• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

含肿瘤基质的 3D 球体阵列:研究纳米颗粒渗透的工具。

Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration.

机构信息

Targeted Therapeutics, Department of Biomaterials Science and Technology, MIRA Institute, University of Twente, Enschede, The Netherlands.

Applied Microfluidics for BioEngineering Research, MIRA Institute, University of Twente, Enschede, The Netherlands.

出版信息

J Control Release. 2016 Dec 28;244(Pt B):257-268. doi: 10.1016/j.jconrel.2016.09.004. Epub 2016 Sep 9.

DOI:10.1016/j.jconrel.2016.09.004
PMID:27616660
Abstract

Nanoparticle penetration through tumor tissue after extravasation is considered as a key issue for tumor distribution and therapeutic effects. Most tumors possess abundant stroma, a fibrotic tissue composed of cancer-associated fibroblasts (CAFs) and extracellular matrix (ECM), which acts as a barrier for nanoparticle penetration. There is however a lack of suitable in vitro systems to study the tumor stroma penetration of nanoparticles. In the present study, we developed and thoroughly characterized a 3D co-culture spheroidal array to mimic tumor stroma and investigated the penetration of silica and PLGA nanoparticles in these spheroids. First, we examined human breast tumor patient biopsies to characterize the content and organization of stroma and found a high expression of alpha-smooth muscle actin (α-SMA; 40% positive area) and collagen-1 (50% positive area). Next, we prepared homospheroids of 4T1 mouse breast cancer cells or 3T3 mouse fibroblasts alone as well as heterospheroids combining 3T3 and 4T1 cells in different ratios (1:1 and 5:1) using a microwell array platform. Confocal live imaging revealed that fibroblasts distributed and reorganized within 48h in heterospheroids. Furthermore, immunohistochemical staining and gene expression analysis showed a proportional increase of α-SMA and collagen in heterospheroids with higher fibroblast ratios attaining 35% and 45% positive area at 5:1 (3T3:4T1) ratio, in a good match with the clinical breast tumor stroma. Subsequently, we studied the penetration of high and low negatively charged fluorescent silica nanoparticles (30nm; red and 100 or 70nm; green; zeta potential: -40mV and -20mV) and as well as Cy5-conjugated pegylated PLGA nanoparticles (200nm, -7mV) in both homo- and heterospheroid models. Fluorescent microscopy on spheroid cryosections after incubation with silica nanoparticles showed that 4T1 homospheroids allowed a high penetration of about 75-80% within 24h, with higher penetration in case of the 30nm nanoparticles. In contrast, spheroids with increasing fibroblast amounts significantly inhibited NP penetration. Silica nanoparticles with a less negative zeta potential exhibited lesser penetration compared to highly negative charged nanoparticles. Subsequently, similar experiments were conducted using Cy5-conjugated pegylated PLGA nanoparticles and confocal laser scanning microscopy; an increased nanoparticle penetration was found in 4T1 homospheroids until 48h, but significantly lower penetration in heterospheroids. Furthermore, we also developed human homospheroids (MDA-MB-231 or Panc-1 tumor cells) and heterospheroids (MDA-MB-231/BJ-hTert and Panc-1/pancreatic stellate cells) and performed silica nanoparticle (30 and 100nm) penetration studies. As a result, heterospheroids had significantly a lesser penetration of the nanoparticles compared to homospheroids. In conclusion, our data demonstrate that tumor stroma acts as a strong barrier for nanoparticle penetration. The 30-nm nanoparticles with low zeta potential favor deeper penetration. Furthermore, the herein proposed 3D co-culture platform that mimics the tumor stroma, is ideally suited to systematically investigate the factors influencing the penetration characteristics of newly developed nanomedicines to allow the design of nanoparticles with optimal penetration characteristics.

摘要

纳米粒子在渗出后穿透肿瘤组织被认为是肿瘤分布和治疗效果的关键问题。大多数肿瘤都有丰富的基质,即由癌相关成纤维细胞(CAFs)和细胞外基质(ECM)组成的纤维组织,它是纳米粒子穿透的屏障。然而,目前缺乏合适的体外系统来研究纳米粒子对肿瘤基质的穿透。在本研究中,我们开发并彻底表征了一种 3D 共培养的球形阵列,以模拟肿瘤基质,并研究了二氧化硅和 PLGA 纳米粒子在这些球体中的穿透情况。首先,我们检查了人类乳腺癌患者活检,以表征基质的含量和组织,并发现α-平滑肌肌动蛋白(α-SMA;阳性区域 40%)和胶原蛋白-1(50%阳性区域)的高表达。接下来,我们使用微井阵列平台制备了单独的 4T1 小鼠乳腺癌细胞或 3T3 小鼠成纤维细胞的同质球体,以及将 3T3 和 4T1 细胞以不同比例(1:1 和 5:1)组合的异质球体。共聚焦活细胞成像显示,成纤维细胞在异质球体中分布并在 48 小时内重新组织。此外,免疫组织化学染色和基因表达分析显示,异质球体中 α-SMA 和胶原蛋白的比例随着成纤维细胞比例的增加而增加,在 5:1(3T3:4T1)比例下达到 35%和 45%的阳性区域,与临床乳腺癌基质非常匹配。随后,我们研究了高电荷和低电荷负荧光二氧化硅纳米粒子(30nm;红色和 100 或 70nm;绿色;Zeta 电位:-40mV 和-20mV)以及 Cy5 标记的聚乙二醇化 PLGA 纳米粒子(200nm,-7mV)在同质和异质球体模型中的穿透情况。在与二氧化硅纳米粒子孵育后对球体冷冻切片进行荧光显微镜检查显示,4T1 同质球体在 24 小时内允许约 75-80%的高穿透率,30nm 纳米粒子的穿透率更高。相比之下,随着成纤维细胞数量的增加,球体显著抑制了 NP 的穿透。具有较低 Zeta 电位的纳米粒子表现出比高电荷纳米粒子更小的穿透性。随后,使用 Cy5 标记的聚乙二醇化 PLGA 纳米粒子进行了类似的实验,并进行了共聚焦激光扫描显微镜检查;发现 4T1 同质球体中的纳米粒子穿透性在 48 小时内增加,但异质球体中的穿透性明显降低。此外,我们还开发了人源同质球体(MDA-MB-231 或 Panc-1 肿瘤细胞)和异质球体(MDA-MB-231/BJ-hTert 和 Panc-1/胰腺星状细胞),并进行了二氧化硅纳米粒子(30 和 100nm)穿透研究。结果表明,与同质球体相比,异质球体的纳米粒子穿透性明显较低。总之,我们的数据表明,肿瘤基质是纳米粒子穿透的强大屏障。具有低 Zeta 电位的 30nm 纳米粒子有利于更深的穿透。此外,本文提出的模拟肿瘤基质的 3D 共培养平台非常适合系统地研究影响新型纳米药物穿透特性的因素,从而设计具有最佳穿透特性的纳米粒子。

相似文献

1
Tumor stroma-containing 3D spheroid arrays: A tool to study nanoparticle penetration.含肿瘤基质的 3D 球体阵列:研究纳米颗粒渗透的工具。
J Control Release. 2016 Dec 28;244(Pt B):257-268. doi: 10.1016/j.jconrel.2016.09.004. Epub 2016 Sep 9.
2
Evaluation of paclitaxel-loaded polymeric nanoparticles in 3D tumor model: impact of tumor stroma on penetration and efficacy.载紫杉醇聚合物纳米粒在 3D 肿瘤模型中的评价:肿瘤基质对渗透和疗效的影响。
Drug Deliv Transl Res. 2023 May;13(5):1470-1483. doi: 10.1007/s13346-023-01310-1. Epub 2023 Feb 28.
3
3D cellular spheroids as tools for understanding carboxylated quantum dot behavior in tumors.3D 细胞球体作为理解肿瘤中羧基化量子点行为的工具。
Biochim Biophys Acta Gen Subj. 2018 Apr;1862(4):914-923. doi: 10.1016/j.bbagen.2017.12.014. Epub 2017 Dec 27.
4
FGF2 engineered SPIONs attenuate tumor stroma and potentiate the effect of chemotherapy in 3D heterospheroidal model of pancreatic tumor.FGF2 工程化 SPIONs 可减弱肿瘤基质并增强三维异质球体胰腺肿瘤模型中化疗的效果。
Nanotheranostics. 2020 Jan 1;4(1):26-39. doi: 10.7150/ntno.38092. eCollection 2020.
5
Polymeric nanofiber leveraged co-delivery of anti-stromal PAK1 inhibitor and paclitaxel enhances therapeutic effects in stroma-rich 3D spheroid models.聚合物纳米纤维介导的抗基质 PAK1 抑制剂和紫杉醇共递送增强了富含基质的 3D 球体模型中的治疗效果。
Int J Pharm. 2024 May 10;656:124078. doi: 10.1016/j.ijpharm.2024.124078. Epub 2024 Apr 2.
6
Spheroid formation and invasion capacity are differentially influenced by co-cultures of fibroblast and macrophage cells in breast cancer.在乳腺癌中,成纤维细胞和巨噬细胞的共培养对球体形成和侵袭能力有不同的影响。
Mol Biol Rep. 2014 May;41(5):2885-92. doi: 10.1007/s11033-014-3144-3. Epub 2014 Jan 28.
7
Light sheet fluorescence microscopy versus confocal microscopy: in quest of a suitable tool to assess drug and nanomedicine penetration into multicellular tumor spheroids.光片荧光显微镜与共聚焦显微镜:寻找合适的工具评估药物和纳米药物渗透入多细胞肿瘤球体。
Eur J Pharm Biopharm. 2019 Sep;142:195-203. doi: 10.1016/j.ejpb.2019.06.019. Epub 2019 Jun 20.
8
Enhanced uptake and transport of PLGA-modified nanoparticles in cervical cancer.聚乳酸-羟基乙酸共聚物修饰的纳米颗粒在宫颈癌中的摄取和转运增强
J Nanobiotechnology. 2016 Apr 22;14:33. doi: 10.1186/s12951-016-0185-x.
9
Three dimensional spheroid cell culture for nanoparticle safety testing.用于纳米颗粒安全性测试的三维球体细胞培养
J Biotechnol. 2015 Jul 10;205:120-9. doi: 10.1016/j.jbiotec.2015.01.001. Epub 2015 Jan 14.
10
Nanoparticles Penetrate into the Multicellular Spheroid-on-Chip: Effect of Surface Charge, Protein Corona, and Exterior Flow.纳米颗粒穿透多细胞球芯片:表面电荷、蛋白冠和外部流动的影响。
Mol Pharm. 2017 Dec 4;14(12):4618-4627. doi: 10.1021/acs.molpharmaceut.7b00726. Epub 2017 Nov 13.

引用本文的文献

1
Cancer-associated fibroblasts in cancer drug resistance and cancer progression: a review.癌症相关成纤维细胞在癌症耐药性和癌症进展中的作用:综述
Cell Death Discov. 2025 Jul 24;11(1):341. doi: 10.1038/s41420-025-02566-x.
2
Autonomous Activation of a Gated Chemiluminescent Photosensitizer Enables Targeted Photodynamic Therapy in Tumor Cells.门控化学发光光敏剂的自主激活可实现肿瘤细胞的靶向光动力疗法。
J Am Chem Soc. 2025 Aug 6;147(31):27822-27834. doi: 10.1021/jacs.5c06761. Epub 2025 Jul 22.
3
Biomimetic Tumour Model Systems for Pancreatic Ductal Adenocarcinoma in Relation to Photodynamic Therapy.
用于胰腺导管腺癌光动力治疗的仿生肿瘤模型系统
Int J Mol Sci. 2025 Jul 2;26(13):6388. doi: 10.3390/ijms26136388.
4
Simulation of the Diffusion Characteristics of Multifunctional Nanocarriers in Tumor Tissues Using Lattice Gas Automata and the Lattice Boltzmann Method.使用格子气自动机和格子玻尔兹曼方法模拟多功能纳米载体在肿瘤组织中的扩散特性
Bioengineering (Basel). 2025 Apr 18;12(4):429. doi: 10.3390/bioengineering12040429.
5
Osteosarcoma tumor microenvironment: the key for the successful development of biologically relevant 3D in vitro models.骨肉瘤肿瘤微环境:构建具有生物学相关性的体外3D模型并取得成功的关键因素。
In Vitro Model. 2022 Jan 18;1(1):5-27. doi: 10.1007/s44164-022-00008-x. eCollection 2022 Feb.
6
Construction of in-situ self-assembled agent for NIR/PET dual-modal imaging and photodynamic therapy for hepatocellular cancer.构建用于近红外/正电子发射断层扫描双模态成像和光动力治疗肝癌的原位自组装试剂。
J Nanobiotechnology. 2024 Oct 10;22(1):614. doi: 10.1186/s12951-024-02879-6.
7
Advances in the Toxicity Assessment of Silver Nanoparticles Derived from a Extract for Monolayers and Spheroids.从 提取物中评估银纳米粒子的毒性进展:单层和球体。
Biomolecules. 2024 May 22;14(6):611. doi: 10.3390/biom14060611.
8
Ultrasmall Gold Nanoparticles Radiolabeled with Iodine-125 as Potential New Radiopharmaceutical.超小尺寸的金纳米粒子经碘-125 放射性标记后,有望成为新型放射性药物。
ACS Appl Bio Mater. 2024 Feb 19;7(2):1240-1249. doi: 10.1021/acsabm.3c01158. Epub 2024 Feb 7.
9
Next-Generation CEA-CAR-NK-92 Cells against Solid Tumors: Overcoming Tumor Microenvironment Challenges in Colorectal Cancer.下一代抗实体瘤的CEA-CAR-NK-92细胞:克服结直肠癌中的肿瘤微环境挑战
Cancers (Basel). 2024 Jan 16;16(2):388. doi: 10.3390/cancers16020388.
10
Effect of Polyplex Size on Penetration into Tumor Spheroids.多聚物复合物大小对肿瘤球体渗透的影响。
Mol Pharm. 2023 Nov 6;20(11):5515-5531. doi: 10.1021/acs.molpharmaceut.3c00397. Epub 2023 Oct 9.